Autophagy is a major cellular metabolic pathway that facilitates degradation of a subset of long-lived proteins and cytoplasmic organelles in eukaryotic cells. This pathway plays a vital role in preserving the cellular homeostasis of the cells themselves, in addition to maintaining the normal physiological state of cell renewal. Many stressors, such as starvation, ischaemia and oxidative stress can induce autophagy. In addition to its physiological roles, autophagy also occurs in a wide variety of pathological processes, including tumour progression, metabolic disorders, and neurodegenerative and lung diseases. In recent years, a growing body of evidence has shown that autophagy also plays a key role in the development of mammalian diseases, a function that has garnered substantial attention and study. An in-depth understanding of the molecular role that autophagy plays in pathological settings is vital for both the diagnosis and treatment of mammalian diseases and will aid in the search for novel targets for therapeutic drug intervention. Here, we provide an integrated review of recent studies implicating autophagy dysfunction in the progression of mammalian disorders and summarize research suggesting that the molecular pathways involved in autophagy could serve as potential therapeutic targets.
Introduction
Autophagy is a tightly regulated process that facilitates degradation of overabundant or malfunctioning cellular components, including damaged organelles, misfolded proteins, invasive microorganisms and cells themselves [1, 2] . There are several different types of autophagy: macroautophagy, chaperone-mediated autophagy (CMA), microautophagy and non-canonical autophagy, such as LC3-associated phagocytosis (LAP) [3] . In LAP, elements of the autophagy pathway conjugate LC3 to phagosomes, which contain engulfed particles, including dying cells.
Although most types of autophagy occur in most eukaryotic cells, the term 'autophagy' is commonly used to describe macroautophagy (and will be used herein). The process of autophagy can be broken down into a series of sequential stages (figure 1). First, signal transduction pathways, frequently regulated by mTOR, initiate autophagy in response to a stimulus. Next, during the vesicle nucleation stage, the VPS34-Beclin-1 and PI3KIII complexes mediate the formation of an isolation membrane, also known as a phagophore. The Atg5-Atg12-Atg16 complex and the Atg8/LC3 protein, a ubiquitin-like protein which is processed by Atg4 to expose its carboxyl terminal glycine residue, regulate the extension stage, in which the phagocytic membrane elongates to form bilayer vesicles called autophagosomes. The origin of autophagosomes has become a hot issue in the field of autophagy research. Some researchers suggest that the autophagosome membrane is a double-layer membrane reconstituted in the pre-autophagosomal structure, while other researchers propose that the membrane is derived from certain organelles that cells already possess, such as the endoplasmic reticulum (ER), Golgi apparatus [4] , endosomes and mitochondria. It has been shown that, in mammalian cells, autophagosomes are produced at the site of contact between the ER and mitochondria [5] . Finally, in the degradation and recycling stage, autophagosomes fuse with lysosomes to form autolysosomes that degrade the autophagosome contents. Free amino acids, nucleotides, fatty acids and other degradative products are released into the cytoplasm and recycled; therefore, autophagy acts as a housekeeping mechanism to maintain cellular homeostasis.
In mammals, autophagy plays a vital role in maintenance of physiological steady state, biosynthesis of macromolecules, cellular development, tissue remodelling and adaptation to the environment [6, 7] . Impaired autophagic activity has been linked to numerous diseases, including cancer, heart disease, immunological disorders and neurodegenerative diseases [8] . In the sections below, we summarize the mechanisms that regulate autophagy and discuss how improper regulation contributes to mammalian diseases. A greater understanding of the role that autophagy plays in disease progression could lead to substantial improvements in the diagnosis and treatment of these illnesses.
Regulation of autophagy
Autophagy is regulated by four key protein complexes, each of which is responsible for regulating a distinct stage. First, the ULK1 protein kinase complex plays an important role in the early stages of autophagosome formation and is mainly composed of the ULK1, Atg13 and FIP200 proteins. The ULK1 complex regulates initiation of autophagy by specifying the site of formation of the precursor membrane. The ULK1 protein contains multiple phosphorylation sites, including Ser757, Ser317 and Ser556, that can be phosphorylated by AMPK and mTOR [9] . The different ULK1 phosphorylation sites may play distinct roles in autophagy by serving in either an inhibitory or activating manner [10] . Second, the PI3 K type III complex, composed of VPS34, p150, Beclin-1 and Atg14, plays a key role in the nucleation and extension of autophagosomes. The complex could promote generation of PI3P, which serves as landing pad for various autophagy effectors. Third, the Atg12-coupled complex consists mainly of Atg12, Atg5 and Atg16. Atg16 is noncovalently associated with Atg12-Atg5, which is necessary for localization of Atg5 and Atg12 to the pre-autophagosomal structure. The complex localizes to the outer surface of the precursor membrane and mediates the final step of LC3 conjugation to phosphatidylethanolamine (PE), which is vital to the formation of autophagosomes. Finally, LC3 is cleaved by ATG4 to form LC3-I, which is conjugated to PE to form LC3-II, a reaction that requires Atg7 and Atg3. LC3-II localizes to the inner and outer layers of the autophagosome, promoting expansion and closure of phagophores to form intact autophagosomes.
The PI3 K/Akt/mTOR pathway is the canonical signal transduction pathway associated with regulation of autophagy [11] , although this pathway is also known to regulate cell division and promote protein translation. mTOR phosphorylation can inhibit the autophagic activity of cells, and the mTOR inhibitor rapamycin has been shown to suppress mTOR phosphorylation and thereby activate the autophagic activity. Other signalling pathways regulating autophagy include the Ras/Raf/ERK [12] , calcium/calmodulin-dependent protein kinase-II (CaMK-II) [13] , and mTOR-independent inositol signalling pathways [14] . Importantly, failure to precisely control these signalling networks involved in regulating autophagic activity can lead to a variety of diseases.
Autophagy and mammalian diseases
Autophagic activity increases under conditions of nutritional deficiency, structural remodelling, oxidative stress, infection and other pathophysiological conditions [15] . Defects in autophagy can lead to many serious pathological disorders, such as cancer [16] , immunity and inflammation, neurodegenerative disease and heart diseases (table 1).
(a) Cancer
There are certain relations between inhibition of autophagy and occurrence of a tumour. Senescent and damaged proteins and organelles, derived from autophagy dysfunction, are potential sources of reactive oxygen species, which cause genomic damage, resulting in chromosomal instability and eventually tumorigenesis [36] . Chemotherapy and radiotherapy treatment can activate autophagy, thereby inducing autophagic cell death in mammalian tissue. In chemical carcinogen-induced hepatoma cells, autophagy decreased in the pre-cancerous nodules, and lysosomal enzyme activity was significantly reduced in autophagic vacuoles isolated from a murine model of hepatocellular carcinoma [37] . Human breast, ovarian and prostate cancers are found to lack the necessary gene for autophagy, BECN1, which was assessed lysosome pre-autophagosomal structure autophagosome autophagosome autophagolysosome Figure 1 . Stages of macroautophagy. During the nucleation phase, an isolation membrane, also known as a phagophore, engulfs protein aggregates and damaged organelles. The isolation membrane then extends, and the phagocytic membrane elongates to form a bilayer vesicle, referred to as an autophagosome. Autophagosomes fuse with lysosomes to form autolysosomes, which degrade the vesicular contents. After degradation, free amino acids, nucleotides, fatty acids and other components are released into the cytoplasm and recycled. (Online version in colour.)
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according to human tumour sequencing data from the database Cancer Genome Atlas (TCGA) [38] . Autophagy has different effects at different stages of tumour development. In the early stages of tumorigenesis, autophagy inhibits tumorigenesis, whereas in the later stages of tumour growth, autophagy promotes tumour development. Autophagy can alleviate the stimuli that cells experience (such as nutrition or energy supply) and support the survival effect of cells. Kang et al. found that receptor for advanced glycation end products (RAGE) increases the rate of autophagy and limits apoptosis in human pancreatic cancer cells in vitro [39] . The protective effect of unfolded protein response (UPR) on cancer cells also indicates that autophagy plays a role in protecting human cancer cells in the hypoxic microenvironment [40] . Thus, the association of cancer and autophagy is complex and worth studying further.
(b) Heart disease
The effects of autophagy on cardiovascular diseases is worthy of further study [41] . Autophagic activity and the expression of autophagy-related genes varies dynamically during the progression of heart failure. During the 14 days after transverse aortic constriction (TAc) surgery in mice [42] , a period of compensatory cardiac function, expression of Atg5 and Atg7 was shown to increase, followed by increased expression of Beclin-1. Additionally, a greater number of autophagosomes appeared, leading to active autophagy. During the decompression of cardiac function period, 14-28 days after surgery, expression of Atg5, Atg7 and Beclin-1 were comparable to basal levels, suggesting that there was no significant change in the formation of autophagosomes; however, p62 was upregulated and degradation of autophagosomes was significantly inhibited. Concurrently, expression of LC3 increased significantly, and there was an accumulation of autophagic bodies, indicative of impairment of the clearance function of autophagosomes.
It has been shown that autophagy plays a significant role in the development and progression of cardiovascular disease. Treatment of neonatal mouse cardiomyocytes with an AdAtg7-RNAi adenovirus significantly reduced the number of viable cells. Furthermore, lack of Atg5 resulted in almost complete inhibition of autophagy, with a concomitant overaccumulation of organelles and intensification of cardiac hypertrophy and heart failure in mice [43] . When Beclin-1 transgenic mice were under pressure overload, autophagy in Beclin-1 þ/2 transgenic mice decreased by about 50%, and cardiac function was significantly improved compared with that observed in wild-type mice [44] .
In myocardial ischaemia-reperfusion injury, autophagy may play a different role [45] . In the initial stages of ischaemia, autophagy plays a protective role in the myocardium; however, during reperfusion, autophagy can cause cellular damage, leading to excessive myocardial cell death. Clearly, varying levels of autophagic activity have different effects on the myocardium, and the same level of autophagy can have a different effect in the same disease depending on the stage of disease progression. Thus, determining the precise role of autophagy during different stages of heart failure will help in further understanding disease pathogenesis and provide novel strategies for the effective prevention and treatment of heart disease.
(c) Immunity and inflammation
In recent years, in vitro and in vivo experiments have shown that autophagy is a key mediator of immunity and inflammation [46] . Autophagy is involved in the regulation, maintenance, and control of the inflammatory response and, importantly, prevents excessive inflammatory responses [47, 48] . Autophagy has been linked to the pathogenesis of a variety of inflammatory and autoimmune diseases, such as Crohn's disease [49] , inflammatory bowel disease [50] , Zika virus infection [51] and lupus [52] .
Autophagy can also present viral antigens to activate an adaptive immune response [52, 53] . In the traditional MHC class I pathway, autophagy involves loading of MHC class I molecules onto the cell surface by the Golgi apparatus and performing antigen processing. Autophagy is also concerned in cross-presentation, present in dendritic cells and macrophages. The lysosomal system plays a prominent role in MHC class II molecules and is associated with autophagy antigen presentation. Autophagosomes transport substances into lysosomes and are important sources of intracellular MHC class II antigens. MHC class II-positive cells, such as dendritic cells, B cells and epithelial cells, have been shown to form autophagosome-like structures [54] . In T cells, autophagy plays both pro-survival and pro-death roles. Upon T cell receptor (TCR) stimulation, Atg5-deficient mouse T cells do not proliferate. Consistent with this observation, reduced numbers of CD4 þ and CD8 þ T cells have been observed in Agt5-deficient mice. Beclin-1-deficient mouse CD4 þ T lymphocytes are more susceptible to apoptosis upon TCR stimulation [55] . In contrast, other studies have found that autophagy is involved in T cell death. Owing to a deficiency in reactive T cells, mice deficient for the Beclin-1/Atg6 gene are resistant to experimental autoimmune encephalomyelitis (EAE) [56] . In innate immunity [57] , autophagy contributes to the effector response downstream of the pattern recognition receptor, which in turn promotes phagocytosis and cytokine production [12, 58] [63] . Autophagy plays a protective role in the immune response and in inflammation by regulating the transcriptional response to inflammatory stimuli, removing damaged mitochondria to reduce oxidative stress, regulating endoplasmic reticulum stress, and removing damaged organelles. Defects in autophagy can lead to inflammatory-related metabolic diseases, such as diabetes and obesity [64] . In the mouse liver, inhibition of the autophagy gene Atg7 leads to endoplasmic reticulum stress and insulin resistance [65] . Mice deficient for the autophagy receptor p62 develop obesity and insulin resistance in early adulthood [66] . Therefore, impairments in autophagic regulation of endoplasmic reticulum stress, immune cell homeostasis and/or immune cell activation may lead to associated inflammation, which is the basis of metabolic disease.
(d) Neurodegenerative diseases
Autophagy plays a vital role in the physiological regulation of neurons, and impairments in autophagy have been shown to lead to neuronal pathologies [67] . Under normal physiological conditions, autophagy is active in neurons, characterized by the presence of neuronal and axonal autophagosomes. Importantly, inappropriate or defective autophagy leads to accelerated neuronal death [68] . Furthermore, ageing neurons often accumulate protein aggregates, and autophagy can serve as a mechanism for the removal of protein aggregates. Cells with impaired autophagy cannot clear these aggregates, leading to neuronal cell damage and death.
A substantial number of studies have focused on understanding the role of autophagy in the degradation of misfolded proteins and how this process mediates neuronal cell death in neurodegenerative diseases. In mice, neuron-specific knockout of Atg5 or Atg7 leads to severe neurodegenerative disease, motor function defects, and either formation of protein aggregates or accumulation of inclusion complexes in the cytoplasm [69] . In some neurodegenerative diseases, autophagy acts as a secondary mechanism to degrade cytoplasmic proteins misfolded due to genetic mutations and to prevent their accumulation and aggregation. However, in neurodegenerative diseases, the ubiquitin proteasome system is overwhelmed by the accumulation of misfolded proteins. In Huntington's disease, protein aggregates could sequester mTOR and decrease its kinase activity, which activates autophagy in mice [70] . In addition, the decrease of Beclin-1 expression in patients with Huntington's disease has been noticed. Beclin-1 can also be sequestered by mutant Huntington aggregations and therefore is unable to induce autophagy [71] . The V471A polymorphism in Atg7 was identified through genotyping and the polymorphism was proved to be associated with an earlier disease onset of 4 years in more than 900 European Huntington's disease patients [72] . Thus, when these protein degradation pathways are overwhelmed by the amount of protein aggregates or when autophagic activity is insufficient, neurodegenerative diseases may occur.
Although the relationship between multiple sclerosis and axonal-neuronal degeneration in brain tissue has been known for more than a century, it has been largely ignored. The mechanism of nerve degeneration in multiple sclerosis remains unknown, and no effective means of prevention or treatment has been found. In EAE mice, the levels of Atg5 in T cells and brain tissue are significantly increased [73] , suggesting the presence of a specific association between autophagy and multiple sclerosis. This relationship has important implications for our understanding of the disease and the development of new drugs.
Therapeutic targeting of autophagy
Various clinical interventions increase autophagy as a therapeutic strategy. Cancer is the most active disease as regards attempts to manipulate the activity of autophagy, and there have been dozens of clinical trials using chloroquine or hydroxychloroquine in combination with other drugs to inhibit autophagy in cancer [74] . The autophagy inducer rapamycin inhibited the kinase activity of mTOR in mantle cell lymphoma, renal cell carcinoma and metastatic breast cancer cells and inhibited cell proliferation [75] . In heart disease, rapamycin administration increased autophagic flux and induced cardiac tube degeneration, and regulated the expression of genes associated with abnormal cardiac development during cardiac tube formation in chick embryos [41] . In the case of myocardial infarction, rapamycin protected isolated mouse hearts and cardiomyocytes from ischaemia-reperfusion injury [76] . In addition, Chen et al. used a similar ischaemiareperfusion model and found decreased cell death and infarct size after rapamycin treatment in female mice [77] . In neurodegenerative diseases, rapamycin and a derivative of rapamycin, CCI-779, can improve motor neuron functioning in fly and mouse models of Huntington's disease [78] .
Other drugs related to autophagy have also been reported. For example, the small molecule Bcl-2 inhibitor ABT-737 had a significant effect on haematological tumours and small-cell lung cancer, and sensitization in combination with other chemotherapy drugs [79] . Imipramine, a tricyclic antidepressant, increased autophagy and showed a moderate therapeutic benefit in glioma-containing animals [80] . Ticlopidine, an anticoagulant inhibitor of the purinergic receptor P2Y12, enhanced imipramine, elevated cAMP, an autophagy modulator, decreased cell viability in culture, and increased survival of glioma-bearing mice [80] . Therefore, a new understanding of potential mechanisms of oncology and other diseases may reveal new potential targets for disease therapy.
Conclusion
Autophagy plays a vital role in many pathophysiological processes, including heart disease, immunological disorders and inflammation, neurodegenerative diseases, and cancer. Consequently, regulation of autophagic activity may be a viable option to treat these diseases. In different disease states, it remains unclear how the body induces and regulates autophagy, how levels of autophagic activity play a role during distinct stages, and whether autophagy promotes or inhibits the development of the disease. Furthermore, the rsbl.royalsocietypublishing.org Biol. Lett. 14: 20170540 determinants of whether autophagy is beneficial or pathological in the context of specific diseases need to be defined. Additional studies may resolve these issues and provide novel insights into the development of disease.
Chemical modulators of autophagy have potentially broad applications in the treatment of diseases; however, the use of these drugs in the regulation of autophagy is challenging. Currently, there are only a limited number of available chemical modulators of this process; developing more drugs that target the regulation of autophagy in different cell types could lead to novel therapies for disease treatment. However, drug research based on autophagy is also in its infancy, and most studies are focused on detecting autophagy-related proteins rather than identifying novel chemical modulators of the process. In future, it would be better to understand the autophagy dynamics of the disorder to be treated in order to best tailor the most appropriate treatment for each disease.
Further development of autophagy-based disease therapeutics must wait for the emergence of more acute pharmacological tools inducing autophagy, and more selective molecular targets in autophagy, and we should aim to understand the autophagy dynamics of the disorder to tailor the treatment for the disease.
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